Table 1.
Descriptive statistics of cost-effectiveness results and peer-reviewed articles on rotavirus vaccines included the analysis.
| Number of ratios reported in Tufts registries (%) | Number of ratios reported in Tufts registries plus sensitivity analyses extracted (%) | Number of articles reported in Tufts registries plus sensitivity analyses* (%) | |
|---|---|---|---|
| Sample size | 483 | 1,345 | 68 |
| Study characteristics | |||
| Region | |||
| Sub-Saharan Africa | 176 (36.4) | 440 (32.7) | 14 (20.6) |
| High-income | 51 (10.6) | 339 (25.2) | 29 (42.6) |
| Southeast Asia, East Asia & Oceania | 69 (14.3) | 177 (13.2) | 12 (17.6) |
| Latin America & Caribbean | 57 (11.8) | 137 (10.2) | 8 (11.8) |
| Central Europe, Eastern Europe, & Central Asia | 51 (10.6) | 107 (8.0) | 5 (7.4) |
| North Africa and the Middle East | 35 (7.2) | 62 (4.6) | 10 (14.7) |
| South Asia | 44 (9.1) | 83 (6.2) | 11 (16.2) |
| Year published | |||
| 2005 | 1 (0.2) | 6 (0.4) | 1 (1.5) |
| 2006 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2007 | 12 (2.5) | 59 (4.4) | 3 (4.4) |
| 2008 | 8 (1.7) | 43 (3.2) | 5 (7.4) |
| 2009 | 14 (2.9) | 226 (16.8) | 10 (14.7) |
| 2010 | 78 (16.1) | 434 (32.3) | 5 (7.4) |
| 2011 | 81 (16.8) | 183 (13.6) | 8 (11.8) |
| 2012 | 17 (3.5) | 54 (4.0) | 7 (10.3) |
| 2013 | 7 (1.4) | 27 (2.0) | 5 (7.4) |
| 2014 | 15 (3.1) | 27 (2.0) | 6 (8.8) |
| 2015 | 232 (48.0) | 253 (18.8) | 10 (14.7) |
| 2016 | 2 (0.4) | 14 (1.0) | 2 (2.9) |
| 2017 | 16 (3.3) | 19 (1.4) | 6 (8.8) |
| Study methods | |||
| Cost discount rate | |||
| < 3% | 5 (1.0) | 95 (7.1) | 10 (14.7) |
| 3% | 457 (94.6) | 1,065 (79.2) | 50 (73.5) |
| > 3% | 21 (4.3) | 185 (13.8) | 15 (22.1) |
| Health outcome measure | |||
| QALYs | 42 (8.7) | 316 (23.5) | 27 (39.7) |
| DALYs | 441 (91.3) | 1,029 (76.5) | 41 (60.3) |
| QALY/DALY discount rate | |||
| <3% | 12 (2.5) | 181 (13.5) | 19 (27.9) |
| 3% | 453 (93.8) | 1,052 (78.2) | 52 (76.5) |
| >3% | 18 (3.7) | 112 (8.3) | 17 (25.0) |
| Perspective | |||
| Societal | 105 (21.7) | 329 (24.5) | 38 (55.9) |
| Limited societal | 94 (19.5) | 478 (35.5) | 11 (16.2) |
| Healthcare payer | 272 (56.3) | 521 (38.7) | 50 (73.5) |
| Health sector | 12 (2.5) | 17 (1.3) | 3 (4.4) |
| Time Horizon | |||
| Lifetime | 241 (49.9) | 307 (22.8) | 15 (22.1) |
| Less than lifetime | 242 (50.1) | 1,038 (77.2) | 53 (77.9) |
| Vaccine characteristics | |||
| Type of vaccine | |||
| Monovalent | 180 (37.3) | 488 (36.3) | 48 (70.6) |
| Pentavalent | 152 (31.5) | 318 (23.6) | 34 (52.9) |
| Monovalent & Pentavalent | 151 (31.3) | 579 (43.0) | 6 (8.8) |
| Median (IQR) | Median (IQR) | ||
| Vaccine coverage | 83 (70,94) | 75 (70,90) | 68 |
| Vaccine cost (2017 USD) | $6.41 (4.85, 9.99) | $7.41 (3.61, 59.30) | 68 |
| Vaccine efficacy | 83.7 (63, 86) | 82 (64, 87) | 68 |
| Vaccine effective coverage | 59.5 (53.4, 78.3) | 59.5 (53.8, 82.5) | 68 |
An asterisk (*) denotes that the total number of articles may exceed 68 since some articles examined multiple regions, vaccine characteristics, and cost-effectiveness analyses characteristics. QALY = quality-adjusted life-year, DALY = disability-adjusted life-year, IQR = interquartile range.